Inhibition of Transglutaminase 2 as a Therapeutic Strategy in Celiac Disease—In Vitro Studies in Intestinal Cells and Duodenal Biopsies

Inhibition of Transglutaminase 2 as a Therapeutic Strategy in Celiac Disease—In Vitro Studies in Intestinal Cells and Duodenal Biopsies

Enzymatic modification of gliadin peptides by human transglutaminase 2 (TG2) is a key mechanism in the pathogenesis of celiac disease (CD) and represents a potential therapeutic target. Recently, we have identified the small oxidative molecule PX-12 as an effective inhibitor of TG2 in vitro. In this...

Full description

Bibliographic Details
Main Authors: Sebastian Stricker, Jan de Laffolie, Klaus-Peter Zimmer, Silvia Rudloff
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:International Journal of Molecular Sciences
Subjects:
celiac disease
transglutaminase 2
TG2 inhibitor
PX-12
gliadin transport
Online Access:https://www.mdpi.com/1422-0067/24/5/4795

Internet

https://www.mdpi.com/1422-0067/24/5/4795

Similar Items